Monday Pre-Meeting About ½ of this seminar’s participants met this afternoon in what turned out to b and ad-hoc, informal brainstorming session Key outcome: we need to come out of these three days with a 1-2 campaigns with global/regional and national components; some way to coordinate this work and; support and finance it Two main campaign suggestions: on FTAs and Global Fund There is a plan by MSF to hold an A2M strategy meeting in January/February with a larger group; this must be a follow-up to our meeting this week in Bangkok

Action Items: Short Term and Long Term Short Term – Free Trade Agreements – Barriers to further scale up of treatment – Collapse of key institutions in global response to AIDS and other diseases – Need to widen scope of A2M movement and partners Long Term – Need for reforms in TRIPS agreement – Need a new global framework on right to health integrating IP – Need to address consolidation in pharmaceutical industry – Need to address models of innovation and ownership of knowledge – Need to address technology transfer issues in drug and diagnostics manufacture

Critical Short Term Issues Free Trade Agreements – USA/Asia-Pacific – EU/Asia – EU/Africa – EU/Mercosur – ACTA (counterfeit) Collapse of Health Institutions – Global Fund cancellation of Round 11—need for US$2B in 200 days – Need for major reforms within Global Fund Re-focus activities on A2M/treatment Address overhead/waste Explore re-programming of existing funds – Need to address centralized, privatized procurement of drugs (e.g. Clinton, UNITAID, PEPFAR) – Need to address effect of Global Fund set-backs on marginalized populations at national level WHO privatization (esp. Essential Drugs Department)

Critical Short Term Issues Widening the Movement – Need to address NCDs Targets and commitments by WHO – Need to address HCV/HBV/TB – Need to engage broader health movements – Need to engage other partners key to work on FTAs etc. (e.g. food security groups, Swedish Pirate Party, Occupy Wall St.) – Need to develop grassroots approach to IP/trade/access literacy – Need to outreach to trade ministries Scale Up of Treatment – Encourage LDCS to extend deadline beyond 2016 – Reach out systematically to generic and API producers (esp. in China, Eastern Europe, etc) – Streamline drug pre- qualification and other quality assessment mechanisms – Bring back a discussion of industrial policy to foster local generic production – Quietly support Chinese CL on TDF – Ensure greater, independent oversight of treatment guideliens development

Potential Campaign Strategies: FTAs Lobbying US Congress and White House Demonstrations at US/EU embassies and consulates Demonstration at International AIDS Conference Targeting current negotiations happening from January-March (e.g. Australia) Developing alternative text for trade agreements Outreach to trade ministers Developing new “sexy” media strategy Developing new social media strategy Missing the Target Report on IP Barriers to ART Access